DK3559000T3 - Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf - Google Patents
Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf Download PDFInfo
- Publication number
- DK3559000T3 DK3559000T3 DK17882916.4T DK17882916T DK3559000T3 DK 3559000 T3 DK3559000 T3 DK 3559000T3 DK 17882916 T DK17882916 T DK 17882916T DK 3559000 T3 DK3559000 T3 DK 3559000T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- methods
- benzimidazole derivatives
- benzimidazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016111457 | 2016-12-22 | ||
| CN2017080661 | 2017-04-14 | ||
| PCT/CN2017/117950 WO2018113771A1 (en) | 2016-12-22 | 2017-12-22 | Benzimidazole derivatives, preparation methods and uses theirof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3559000T3 true DK3559000T3 (da) | 2022-06-07 |
Family
ID=62624617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17882916.4T DK3559000T3 (da) | 2016-12-22 | 2017-12-22 | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11053238B2 (da) |
| EP (1) | EP3559000B1 (da) |
| JP (1) | JP7105781B2 (da) |
| KR (1) | KR102543603B1 (da) |
| CN (1) | CN110234652B (da) |
| AU (1) | AU2017379041B2 (da) |
| CA (1) | CA3047876C (da) |
| DK (1) | DK3559000T3 (da) |
| ES (1) | ES2917377T3 (da) |
| TW (1) | TWI732083B (da) |
| WO (1) | WO2018113771A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN111315379A (zh) | 2017-08-15 | 2020-06-19 | 北京轩义医药科技有限公司 | Cdk4/6抑制剂及其用途 |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| EA202190036A1 (ru) | 2018-06-21 | 2021-03-24 | Бетта Фармасьютикалз Ко., Лтд | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение |
| SG11202112229UA (en) * | 2019-05-05 | 2021-12-30 | Qilu Regor Therapeutics Inc | Cdk inhibitors |
| CN111138455B (zh) * | 2020-01-16 | 2022-03-04 | 郑州大学 | 一种手性四氢呋喃并恶嗪稠合苯并咪唑衍生物及其制备方法和用途 |
| WO2021218939A1 (zh) * | 2020-04-28 | 2021-11-04 | 贝达药业股份有限公司 | 稠环化合物及其在医药上的应用 |
| KR102269420B1 (ko) | 2020-09-18 | 2021-06-24 | 전용석 | 긴급대피용 마스크장치 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| US20240140963A1 (en) * | 2021-02-03 | 2024-05-02 | Tuojie Biotech (Shanghai) Co., Ltd. | Fused tricyclic cyclin-dependent kinase inhibitor, and preparation method therefor and pharmaceutical use thereof |
| CN112979567B (zh) * | 2021-03-05 | 2023-07-18 | 中国医科大学 | Cdk12小分子抑制剂的化合物及其应用 |
| WO2022199656A1 (zh) * | 2021-03-24 | 2022-09-29 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| WO2024027631A1 (zh) * | 2022-08-01 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 一种稠三环类衍生物的晶型及制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| EP2594555B1 (en) * | 2010-07-02 | 2018-03-07 | ASKA Pharmaceutical Co., Ltd. | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| SG10202004716RA (en) | 2014-07-24 | 2020-06-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| EP3288939A1 (en) * | 2015-04-17 | 2018-03-07 | AbbVie Inc. | Tricyclic modulators of tnf signaling |
| TWI696617B (zh) * | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| CN105153119B (zh) | 2015-09-11 | 2019-01-01 | 广州必贝特医药技术有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
-
2017
- 2017-12-22 TW TW106145306A patent/TWI732083B/zh active
- 2017-12-22 ES ES17882916T patent/ES2917377T3/es active Active
- 2017-12-22 CA CA3047876A patent/CA3047876C/en active Active
- 2017-12-22 WO PCT/CN2017/117950 patent/WO2018113771A1/en unknown
- 2017-12-22 US US16/471,415 patent/US11053238B2/en active Active
- 2017-12-22 AU AU2017379041A patent/AU2017379041B2/en active Active
- 2017-12-22 EP EP17882916.4A patent/EP3559000B1/en active Active
- 2017-12-22 KR KR1020197020604A patent/KR102543603B1/ko active IP Right Grant
- 2017-12-22 CN CN201780078241.XA patent/CN110234652B/zh active Active
- 2017-12-22 JP JP2019534709A patent/JP7105781B2/ja active Active
- 2017-12-22 DK DK17882916.4T patent/DK3559000T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| US11053238B2 (en) | 2021-07-06 |
| AU2017379041A1 (en) | 2019-07-25 |
| KR20190114971A (ko) | 2019-10-10 |
| WO2018113771A1 (en) | 2018-06-28 |
| CN110234652B (zh) | 2020-11-10 |
| JP7105781B2 (ja) | 2022-07-25 |
| EP3559000A4 (en) | 2020-05-27 |
| EP3559000A1 (en) | 2019-10-30 |
| CN110234652A (zh) | 2019-09-13 |
| ES2917377T3 (es) | 2022-07-08 |
| JP2020504747A (ja) | 2020-02-13 |
| CA3047876C (en) | 2023-08-29 |
| KR102543603B1 (ko) | 2023-06-14 |
| RU2019121937A3 (da) | 2021-02-09 |
| EP3559000B1 (en) | 2022-03-23 |
| AU2017379041B2 (en) | 2021-08-26 |
| TW201829406A (zh) | 2018-08-16 |
| TWI732083B (zh) | 2021-07-01 |
| CA3047876A1 (en) | 2018-06-28 |
| RU2019121937A (ru) | 2021-01-22 |
| US20210130345A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3559000T3 (da) | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf | |
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3464282T3 (da) | Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse | |
| DK3429596T3 (da) | Cykliske dinukleotide forbindelser og brugs metoder | |
| DK3354649T3 (da) | Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3212189T3 (da) | Substituerede chromaner og fremgangsmåde til anvendelse deraf | |
| DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3152956T3 (da) | Systemer og metoder til kommunikation | |
| DK3297637T3 (da) | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf | |
| DK3271347T3 (da) | Antifungale forbindelser og fremstillingsfremgangsmåder | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3445925T3 (da) | Justerbar, kompakt løftekobling og fremgangsmåde til anvendelse | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3137168T3 (da) | Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3265123T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3398598T3 (da) | Sulfonamidderivat og fremstillingsmetode og anvendelse deraf |